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Background: Limited information is available about predictors of short-term outcomes in patients with exacerbation
of chronic obstructive pulmonary disease (eCOPD) attending an emergency department (ED). Such information could
help stratify these patients and guide medical decision-making. The aim of this study was to develop a clinical
prediction rule for short-term mortality during hospital admission or within a week after the index ED visit.
Methods: This was a prospective cohort study of patients with eCOPD attending the EDs of 16 participating hospitals.
Recruitment started in June 2008 and ended in September 2010. Information on possible predictor variables was
recorded during the time the patient was evaluated in the ED, at the time a decision was made to admit the patient to
the hospital or discharge home, and during follow-up. Main short-term outcomes were death during hospital
admission or within 1 week of discharge to home from the ED, as well as at death within 1 month of the index ED visit.
Multivariate logistic regression models were developed in a derivation sample and validated in a validation sample. The
score was compared with other published prediction rules for patients with stable COPD.
Results: In total, 2,487 patients were included in the study. Predictors of death during hospital admission, or within
1 week of discharge to home from the ED were patient age, baseline dyspnea, previous need for long-term home
oxygen therapy or non-invasive mechanical ventilation, altered mental status, and use of inspiratory accessory muscles
or paradoxical breathing upon ED arrival (area under the curve (AUC) = 0.85). Addition of arterial blood gas parameters
(oxygen and carbon dioxide partial pressures (PO2 and PCO2)) and pH) did not improve the model. The same variables
were predictors of death at 1 month (AUC = 0.85). Compared with other commonly used tools for predicting the
severity of COPD in stable patients, our rule was significantly better.
Conclusions: Five clinical predictors easily available in the ED, and also in the primary care setting, can be used to
create a simple and easily obtained score that allows clinicians to stratify patients with eCOPD upon ED arrival and
guide the medical decision-making process.
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Chronic obstructive pulmonary disease (COPD) is a
leading chronic condition in many countries [1]. Patients
can experience exacerbation of COPD (eCOPD) that often
requires assessment in an emergency department (ED)
and hospitalization. Exacerbations play a major role in
the burden of COPD, its evolution, and its cost [2,3].
Some exacerbations can be severe, leading to death or
the need for intubation, whereas others are more moder-
ate, requiring little more than an adjustment of the pa-
tient’s current medical therapy. Currently, ED physicians
must rely largely on their experience and the patient's
personal criteria for gauging how an eCOPD will evolve.
A clinical prediction rule that could help predict eCOPD
evolution would allow ED physicians to make better
informed decisions about treatment.
A couple of severity scores have been developed for
patients with stable COPD [4,5], but these do not apply
to patients with eCOPD. Several studies have attempted
to develop severity scores for eCOPD, but none has
been adopted by clinicians, largely because they do
not include important clinical variables or they have
other methodological problems [6-10]. Several key is-
sues affect the development of severity scores for pa-
tients with eCOPD being evaluated in an ED. To date,
most such studies have included only patients who are
admitted to the hospital, which excludes a significant
percentage of patients with eCOPD [11,12]. Another
limitation is the choice of reliable predictors that can
easily be gathered in the ED. For a clinical prediction
rule to be adopted, its development must follow strict
methodological norms and must be based on easily
available parameters [13,14].
The goal of this study was to develop a clinical prediction
rule for short-term death following eCOPD. We defined
'short term 'as any time during the hospital admission
or within 1 week after discharge from the ED to home.
Data for developing this rule were collected from a large
prospective cohort of patients with eCOPD attending a
number of different EDs.
Methods
This prospective cohort study covered 16 hospitals
belonging to the Spanish National Health Service
(Hospital Costa del Sol, Hospital Valme, Hospital de
Motril, Corporació Sanitaria Parc Taulí, Hospital del
Mar, Hospital Universitario de La Princesa, Hospital
Universitario Gregorio Marañón, Hospital Universitario
La Paz, Hospital de Móstoles, Hospital Marqués de
Valdecilla, Hospital Santa Marina, Hospital San Eloy,
Hospital Galdakao-Usansolo, Hospital Txagorritxu,
Complejo Hospitalario Donostia, and Hospital Cruces).
The Institutional Review Boards of the participating
hospitals approved this project. Patients with eCOPDattending the EDs of any of these hospitals were informed
of the goals of the study, and invited to voluntarily partici-
pate and sign an informed consent form. All information
was kept confidential. Recruitment started in June 2008
and ended in September 2010. A description of the study
protocol was published previously [15].
Patients were eligible for the study if they presented to
the ED with symptoms consistent with eCOPD. COPD
was confirmed if the patient had a forced expiratory
volume in 1 second/forced vital capacity (FEV1/FVC)
quotient of less than 70%. Exacerbation was defined as an
event in the natural course of the disease characterized by
a change in the patient’s baseline dyspnea, cough, and/or
sputum that was beyond normal day to day variations and
may have warranted a change in regular medication in a
patient with underlying COPD [16]. For cases of COPD
newly diagnosed in the ED to be included in the study,
they had to be confirmed by spirometry within 60 days
after the index episode at a time when the patient was
stable [17]. Patients were excluded from the study if, at the
time they were seeing at the ED, they had eCOPD compli-
cated by a comorbidity such as pneumonia, pneumothorax,
pulmonary embolism, lung cancer, or left cardiac insuffi-
ciency. Other exclusion criteria included a diagnosis of
asthma, extensive bronchiectasis, sequelae of tuberculosis,
pleural thickening, or restrictive disease. Patients who did
not wish to participate were also excluded.
Data collected
Data collected upon arrival in the ED included socioeco-
nomic data, information about the patient’s respiratory
function (arterial blood gases, respiratory rate, dyspnea),
consciousness level measured by the Glasgow Coma
Scale (GCS; altered consciousness defined as a score of ≤15
points, unaltered consciousness as a score of >15) [18], and
presence of other pathologies recorded in the Charlson
Comorbidity Index [19]. Additional data collected in the
ED at the time a decision was made to admit or discharge
the patient included the patient’s symptoms, signs, and
respiratory status at that time. All information regarding
the ED evaluation was recorded as it was provided by
the ED physician in charge of the patient.
For patients admitted to the hospital, we collected
additional data from the patient’s medical record and
from a direct interview with the patient on the first day
after admission and on the day of discharge. For patients
discharged from the ED to home, telephone interviews
were conducted with the patient around 1 and 7 days
after discharge to assess hospital readmission and vital
status. We asked all patients to tell us about their
physical activity, general health, and dyspnea level
while in stable condition before the eCOPD index and
at 24 hours after being admitted to the hospital or dis-
charged from the ED to home. We used the Medical
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measure baseline dyspnea.
For all patients with known COPD, additional variables
were collected from medical records, including baseline
severity of COPD as measured by FEV1; hospital admis-
sions for eCOPD during the previous 12 months; baseline
therapy (inhaled short-acting or long-acting beta-agonist,
short-acting or long-acting anticholinergics, oral or inhaled
corticosteroid, theophyllines, and/or need for noninvasive
mechanical ventilation (NIMV) or long-term home oxygen
therapy (LTHOT)); and presence of diabetes, hypertension,
ischemic heart disease and/or valve disease, cor pulmonale,
hepatic disease, peptic ulcer disease, psychiatric disorders,
rheumatic disease, and any history of stroke or deep-vein
thrombosis, and of other conditions needed to determine
the Charlson Comorbidity Index.
Reviewers were trained before data collection, and a pre-
cise manual was developed, which was closely followed for
the collection of data.
Definitions of outcome measure
The main outcomes measured were death occurring during
the hospital admission or within 1 week of discharge to
home from the ED, and death within 1 month of the index
ED visit. Additional outcomes reported in this study were
admission to the hospital and, if admitted, length of hos-
pital stay; admission to the intensive care unit (ICU); need
for invasive mechanical ventilation (IMV); need for NIMV
for 2 or more days when mechanical ventilation was not
used at home before admission; and admission to an
intermediate respiratory care unit (IRCU) for 2 or more
days (a minimum of 2 days was chosen to include only
those patients needing more intensive and prolonged
therapeutic interventions).
Patients were followed by phone or direct interview to
reduce losses to a minimum.
Statistical analysis
The unit of the analysis was the patient. For patients
who had more than one eCOPD requiring an ED visit
during the recruitment period, only the first visit was
considered for the analysis. Assumptions about how
missing data were handled in this study have been de-
scribed elsewhere. In general, missing values were im-
puted. In the case of missing data on basal level of
dyspnea (MRC classification) it was imputed because
class 5 comparison of the mortality rate of this group
of patients with the other MRC categories (1 to 4) gave
P values of less than 0.0001, whereas the P value within
the MRC group 5 was 0.63.
The total sample was randomly divided in two to give
a derivation sample and a validation sample. Descriptive
analyses for both samples included frequency and per-
centages for categorical variables, and mean and standarddeviations for continuous variables. The χ2and Fisher’s
exact tests were used to test for statistical significance
between proportions. For continuous variables, the
Wilcoxon U-test was used.
In order to identify risk factors associated with short-
term mortality in COPD, we performed univariate ana-
lyses in the derivation sample using logistic regression.
Variables that were significant at P = 0.20 were entered
into a multivariate logistic regression model. We per-
formed logistic regression models in the derivation
sample to select separately the variables for prediction
of death. Final predictive factors in the multivariate
analysis were those with a significance level of 0.05.
Beta estimates, odds ratios (ORs) and 95% confidence
intervals (95% CIs) were provided for the multivariate
analysis. We developed a score by assigning a weight to
each risk factor category based on the β parameter
from the multivariate logistic regression. From the
continuous score, four risk categories were created
(mild, moderate, severe, and very severe). We considered
the optimal classifier point as the point that maximized
the sum of sensitivity and specificity. Final models were
also adjusted by the treating hospital to see if that affected
the results.
The predictive accuracy of each model was determined
by calculating the area under the receiver operating
characteristic (ROC) curve (discrimination) (AUC), and
the models were calibrated by means of the Hosmer and
Lemeshow test. We validated all AUCs—that is, those
from the model and those from the continuous and cat-
egorical scores—in the validation sample by deriving the
AUC in this sample [21].
Additional multivariate logistic regressions models
were performed to evaluate the impact on short-term
mortality of arterial blood gas values (pH, PCO2 and PO2)
measured both at the time the patient arrived in the ED
and at the time a decision was made to hospitalize the pa-
tient or discharge them to home from the ED. These were
adjusted by our categorical score.
We compared various outcomes between the four risk
classes of our categorical score. These included ICU
admission; need for IMV; admission to an IRCU; admission
to the hospital and, if admitted, length of hospital stay;
readmissions within 10 days, 1 month, and 2 months
after the index ED visit; and subsequent ED visits in the
2 months following the index ED visit.
To compare the predictive ability of our score, we ap-
plied information from all patients to previously created
predictor scores for mortality in patients with stable COPD.
These included the ADO (age, baseline dyspnea, and
airflow obstruction measured by FEV1%) index [22], the
HADO (health, activity, dyspnea, and airflow obstruction)
score [23], baseline FEV1% classified according to the
Global Initiative for Chronic Obstructive Lung Disease
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COPD combined assessment (baseline dyspnea plus
previous exacerbations over the previous year) [24].
For the latter, we used hospitalizations during the pre-
vious year, as we did not collect the variable 'previous
exacerbations.' Descriptive statistics for the previous
mortality predictor scales (FEV1% classifications) were
computed, and each AUC and its CI were determined
and compared with our score.
All effects were considered significant at P < 0.05, unless
otherwise stated. All statistical analyses were per-
formed using SAS for Windows statistical software, v9.2
(SAS Institute, Inc., Carey, NC) and R© software v2.13.0.
Results
A total of 3,276 episodes were assesses for the study.
Of these, 198 (6%) were excluded because COPD was
complicated by other major pathologies at the time of
ED admission (cardiovascular conditions: 59 (29.8%);
pneumonia: 55 (27.8%); cancer: 21 (10.6%); other re-
spiratory problems, 13 (6.6%); and other conditions, 50
(25.2%)). A further 56 episodes were excluded because
the COPD diagnosis was not confirmed by spirometry
within 60 days of the index episode. Another 145 epi-
sodes were lost because of incomplete data without the
possibility of retrieving the information needed for the
study. Finally, 390 episodes were excluded because the
patient had more than one ED visit. No differences
were observed in mortality (4.4% versus. 2.7%; P = 0.32)
or other parameters, such as arterial blood gas as pH
upon ED arrival (P = 0.52) between episodes excluded
because patients had multiple eCOPD episodes and ep-
isodes included from patients who had only a single
eCOPD episode.
The final population included 2,487 patients. Of these,
1,537 (61.8%) were admitted to the hospital and 950
(38.2%) were discharged from the ED to home.
Comparison of the derivation and validation samples
is shown in Table 1. Variables related to short-term
mortality in the univariate analysis of the derivation
sample are displayed in Table 2. Variables that were also
evaluated, but were not statistically significantly correlated
with outcome, included previous oral corticosteroid use,
chronic renal disease, cerebrovascular disease, chronic
liver disease, edema at ED admission, and four variables
recorded upon ED arrival:O2 saturation, blood pressure,
temperature, and serum glucose.
All variables with P values below 0.20 were entered into a
multivariate logistic regression model. Five parameters
shaped the final model for predicting death during hospital
admission or within 1 week of discharge from the ED
to home: age; previous history of LTHOT or NIMV;
altered consciousness measured by GCS; use of accessory
inspiratory muscles or paradoxical breathing upon EDarrival; and baseline dyspnea measured by the MRC
scale (model AUC = 0.85, 95% CI 0.77 to 0.93). In sep-
arate models, we evaluated the effect on the final
model of the role of arterial blood gases by adding the
values of PO2, PCO2, and pH measured at both ED arrival
and at the time that a decision was made to hospitalize
the patient or discharge them from the ED to home. None
of these was statistically significant.
We assigned a score to each category of the variables
selected in the model based on their parameter esti-
mates. Adding these individual scores yielded a final risk
score that we called the continuous death in eCOPD
(DeCOPD) risk score (AUC = 0.85, 95% CI 0.77 to 0.93)
(Table 3). A categorical DeCOPD score was created by div-
iding the continuous DeCOPD score into four risk categor-
ies (mild, moderate, severe, and very severe) based on the
risk of experiencing the outcome (Figure 1). This yielded an
AUC of 0.84 (95% CI 0.76 to 0.91). Hosmer-Lemeshow
tests were all P > 0.62. The continuous DeCOPD score
(AUC= 0.84; 95% CI 0.77 to 0.92) and the categorical
DeCOPD risk classes (AUC= 0.85; 95% CI 0.78 to 0.92)
were validated in a separate sample (validation sample).
Introducing the treating hospital variable into any model
did not change the model, nor was the individual hospital
significantly related to mortality (P = 0.064 unadjusted;
P = 0.96 adjusted by the DeCOPD continuous score).
The 1-month mortality was tested in the same model.
It had an AUC of 0.85 (95% CI 0.81 to 0.90); AUCs were
0.83 (95% CI 0.78 to 0.88) for the continuous DeCOPD
score and 0.83 (95% CI 0.78 to 0.88) for the categorical
DeCOPD score.
In addition to short-term mortality, other outcomes
that reflect adverse eCOPD evolution (for example, need
for IMV, admission to ICU or IRCU) were compared
between the four risk classes. Differences were observed
across most of the categories for such outcomes (Figure 1).
Specifically, differences between the four risk classes were
observed for short-term mortality, in-hospital mortality,
and 1 month mortality. When the four classes were di-
chotomized in two (score ≥12) the accuracy results for
short-term mortality were: sensitivity 41%, specificity
97%, positive predictive value (PPV) 25%, and negative
predictive value (NPV) 99%. When the cut-off point was
7 or above, the accuracy results for ICU admission, IMV
use, or IRCU admission were: sensitivity 53.9%, specificity
79.05%, PPV 34%, and NPV 89.54%. The relationship of the
DeCOPD categorical score in two categories (score ≥7)
with other outcomes (for example, hospital admission,
length of stay, readmissions or new ED visits) is presented
(see Additional file 1).
Finally, we compared the continuous and categorical
DeCOPD scores with scores created for patients with stable
COPD, including the ADO index, HADO score, GOLD
FEV1% and GOLD COPD combined assessment. The AUC
Table 1 Descriptive characteristics of derivation and validation samples
Derivation Validation P value
N n (%)a N n (%)a
Age, yearsb 1242 72.32 ± 9.81 1244 73.23 ± 9.51 0.02
Male sex 1242 1136 (91.47) 1242 1131 (91.06) 0.72
Baseline FEV 1046 1023
≥50 367 (35.09) 352 (34.41) 0.75
<50 679 (64.91) 671 (65.59)
Charlson Comorbidity Indexb 1243 2.25 ± 1.55 1244 2.89 ± 1.6 0.79
Previous use of LTHOT or NIMV at home 1243 424 (34.11) 1244 417 (33.52) 0.76
Number of COPD-related admissions in the previous 12 monthsbd 1228 0.84 ± 1.37 1223 0.83 ± 1.38 0.65
Altered consciousness 1242 31 (2.50) 1243 39 (3.14) 0.33
Presence of edema 1164 225 (19.33) 1168 211 (18.07) 0.43
Dyspnea upon ED arrival 1182 803 (67.94) 1179 798 (67.68) 0.9
Heart rate upon ED arrivalb 1168 95.51 ± 19.35 1163 94.32 ± 18.69 0.1
Use of inspiratory accessory muscle upon ED arrival 1243 248 (19.95) 1244 262 (21.06) 0.49
Breathing frequency upon ED arrival 1135 1132 0.8
<20 breaths/min 186 (16.39) 188 (16.61)
20 to 24 breaths/min 506 (44.58) 489 (43.2)
>24 breaths/min 443 (39.03) 455 (40.19)
pH upon ED arrival 1147 1148 0.3
≥7.35 986 (85.96) 1005 (87.54)
7.26 to 7.35 136 (11.86) 114 (9.93)
<7.26 25 (2.18) 29 (2.53)
PO2 upon ED arrival 1137 1141 0.77
>60 (O2 saturation >90%) 563 (49.52) 571 (50.04)
45 to 60 (O2 saturation <90%) 420 (36.94) 427 (37.42)
≤45 154 (13.54) 143 (12.53)
PCO2 upon ED arrival 1078 1076 0.65
≤45 603 (55.94) 629 (58.46)
45 to 55 249 (23.1) 235 (21.84)
55 to 65 127 (11.78) 114( 10.59)
>65 99 (9.18) 98 (9.11)
Baseline dyspnea (MRC scale) 1243 1244 0.13
Missing 121(9.73) 129(10.37)
Grade 1 87 (7) 101 (8.12)
Grade 2 321 (25.82) 279 (22.43)
Grade 3 247 (19.87) 254 (20.42)
Grade 4 345 (27.76) 327 (26.29)
Grade 5 122 (9.81) 154 (12.38)
Outcomes
Short-term mortalityc 1243 30 (2.41) 1244 29 (2.33) 0.89
1-month mortality 1243 40 (3.22) 1244 48 (3.86) 0.39
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, FEV forced expiratory volume, LTHOT long-term home oxygen therapy,
NIMV non-invasive mechanical ventilation, PCO2 carbon dioxide partial pressure, PO2 oxygen partial pressure.
aUnless otherwise specified.
bMean ± SD.
cDuring hospital admission or within 1 week of discharge to home from the ED.
dNumber of COPD-related admissions in the previous 12 months, median (25th to 75th percentile): 0 (0–1) in both samples.
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Table 2 Predictors of short-term mortality and 1 month mortality in the derivation sample
Parameter Short-term mortalitya 1 month mortality
OR P value OR P value
Age, yearsb 1.051 0.0237 1.0411 0.0294
Male sex 1.314 0.7120 1.8 0.4226
Baseline FEV: <50 versus ≥50 2.197 0.1185 2.587 0.0365
Charlson Comorbidity Indexb 1.297 0.0016 1.360 <0.0001
Previous use of LTHOT or NIMV at home 4.690 0.0001 4.755 <0.0001
Number of COPD-related admissions in the previous 12 monthsc 1.168 0.1502 1.137 0.187
Altered consciousness 11.87 <0.0001 8.308 <0.0001
Presence of edema 1.056 0.9140 1.246 0.6268
Dyspnea upon ED arrival 3.531 0.0414 1.92 0.1268
Heart rate upon ED arrivalb 1.028 0.0017 1.020 0.0128
Use of inspiratory accessory muscle upon ED arrival 4.026 0.0001 2.79 0.0019
Breathing frequency upon ED arrival
20 to 24 versus <20 3.350 0.2530 2.811 0.1726
>24 versus <20 7.381 0.0529 4.123 0.0585
pH upon ED arrival
7.26 to 7.35 versus ≥7.35 2.631 0.0456 2.086 0.0931
<7.26 versus ≥7.35 7.777 0.0020 7.323 0.0006
PO2 upon ED arrival
45 to 60 versus >60 0.762 0.5431 0.630 0.2350
≤45 versus >60 1.046 0.9379 0.866 0.7764
PCO2 upon ED arrival
46 to 55 versus ≤45 2.8226 0.047 3.003 0.0115
56 to 65 versus ≤45 0.676 0.7150 0.949 0.9463
>65 versus ≤45 8.514 <0.0001 7.413 <0.0001
Baseline dyspnea (MRC scale)
MRC3 versus MRC1 to MRC2 6.398 0.1064 3.335 0.2960
MRC4 versus MRC1 to MRC2 8.035 0.0397 4.810 0.0601
MRC5 versus MRC1 to MRC2 61.599 <0.0001 26.115 <0.0001
Missing versus MRC1 to MRC2 50.583 <0.0001 22.185 <0.0001
Abbreviations: COPD chronic obstructive pulmonary disease, ED emergency department, FEV forced expiratory volume, LTHOT long-term home oxygen therapy,
MRC Medical Research Council, NIMV non-invasive mechanical ventilation, PCO2 carbon dioxide partial pressure, PO2 oxygen partial pressure.
aShort-term mortality: mortality during hospital admission or, if discharged from the ED, in 1 week.
b Variables included as continuous.
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cantly different from these other assessments (Table 4).
Discussion
This study describes the development of a clinical pre-
diction rule for short-term mortality in patients with ex-
acerbations of COPD, derived from a large, multicenter
prospective cohort. This rule predicts death using clin-
ical data generally available in the ED, and also often
available in the primary care setting. Development of
this rule followed proper procedures for derivation and
validation [11,12], and the rule provides excellent pre-
dictive validity.Given how common exacerbations are among patients
with COPD, and the substantial effects of these exacerba-
tions on health, health-related quality of life, and health-
care costs, predicting the severity of exacerbations could
significantly improve both care and allow more targeted
allocation of healthcare resources. To date, however, no
validated clinical prediction rules are available to stratify
all patients experiencing an eCOPD upon their arrival in
an ED, or to provide valid and reliable clinical rules or
scores for predicting short-term outcomes [6,9].
To the best of our knowledge, no prior prospective
cohort studies including both patients admitted to the
hospital and those discharged to home from the ED have
Table 3 Predictors of short-term mortality and 1 month mortality in the derivation sample
Outcome prediction model/parameter Estimate OR 95% CI of the AUC P value Score
Short-term mortalitya
Age, years
75 to 85 versus <75 0.2417 1.273 0.540 to 3.003 0.5808 0
>85 versus <75 1.3062 3.692 1.134 to 12.022 0.0301 3
Previous use of LTHOT or NIMV at home 1.1557 3.176 1.278 to 7.893 0.0128 3
Altered consciousness 1.1852 3.271 1.031 to 10.376 0.0442 3
Use of inspiratory accessory muscle or paradoxical breathing upon ED arrival 1.4740 4.367 1.912 to 9.972 0.0005 4
Baseline dyspnea (MRC scale)
Grade 5 versus grades 1 to 4 2.0456 7.734 2.923 to 20.463 <0.0001 5
Missing versus grades 1 to 4 2.5581 12.912 4.654 to 35.821 <0.0001 5
bDerivation sample: AUCmodel = 0.85 (0.77 to 0.93); AUCscore = 0.85 (0.77 to 0.93) AUCscore _ cat = 0.84 (0.76 to 0.91)
bValidation sample: AUCmodel = 0.88 (0.82 to 0.94); AUCscore = 0.84 (0.77 to 0.92) AUCscore _ cat = 0.85(0.78 to 0.92)
1 month mortality (validation sample)
Age, years
75 to 85 versus <75 0.8199 2.270 1.092 to 4.719 0.0281
>85 versus <75 1.9253 6.857 2.701 to 17.411 <0.0001
Previous use of LTHOT or NIMV at home 1.3737 3.950 1.956 to 7.976 0.0001
Altered consciousness 0.9513 2.589 0.887 to 7.557 0.0817
Use of inspiratory accessory muscle or paradoxical breathing upon ED arrival 1.2508 3.493 1.850 to 6.596 0.0001
Baseline dyspnea (MRC scale)
Grade 5 versus grades 1 to 4 1.1743 3.236 1.581 to 6.625 0.0013
Missing versus grades 1 to 4 1.3324 3.790 1.643 to 8.742 0.0018
bValidation sample: AUCmodel = 0.85 (0.81 to 0.90); AUCscore = 0.83 (0.78 to 0.88); AUCscore _ cat = 0.83 (0.78 to 0.88)
Abbreviations: AUC area under the receiver operating characteristic curve, LTHOT long-term home oxygen therapy, MRC Medical Research Council, NIMV
non-invasive mechanical ventilation.
aShort-term mortality: mortality during hospital admission or, if discharged from the ED, in 1 week.
bAUCs are the results for the whole model, the continuous score, and the categorical score, respectively.
Quintana et al. BMC Medicine 2014, 12:66 Page 7 of 11
http://www.biomedcentral.com/1741-7015/12/66been employed to develop and validate a clinical pre-
diction rule for death using variables commonly avail-
able in the ED [6,9]. Although previous authors have
proposed predictive models for death or ICU admis-
sion, and some have created severity scores for patients
with eCOPD, these did not evaluate such a complete
range of variables as in our study, including arterial
blood gases and other relevant data from the ED, and
this limits their results [7-9,25,26].
The five factors in our final model—age, previous his-
tory of LTHOT or NIMV, use of inspiratory accessory
muscles or paradoxical breathing upon ED arrival, altered
mental status, and baseline dyspnea—have been observed
separately as predictors of poor outcomes in previous
studies [6,8,9,11,26-28]. Age is always a surrogate of other
still unknown variables. Previous use of LTHOT or NIMV
and the baseline level of dyspnea reflect the basal severity
of the patient’s COPD. Altered mental status or the use of
inspiratory accessory muscles upon arrival in the ED indi-
cate acute cardiopulmonary compromise of the current
presentation. Some of the parameters included in our ruleare not modifiable, such as age or previous need of
LTHOT or NIMV at home, which reflect the fragility
of the patient and their disease. Severe baseline dyspnea
can be modified through respiratory rehabilitation pro-
grams. Even for patients with severe COPD who can-
not undertake respiratory rehabilitation, efforts to avoid
new exacerbations or readmissions can be conducted
through programs such as telemedicine or continuity of
care, as has been reported elsewhere [29]. Finally, use of
inspiratory accessory muscles or paradoxical breathing
and altered level of consciousness reflect the severity of
the current exacerbation. These are not permanent but
modifiable and, in conjunction with other factors,
should alert the ED physician to the severity of the pa-
tient’s eCOPD and guide appropriate treatment and
adequate follow-up.
We found that measurement of arterial blood gases
upon ED arrival or at the time a decision is made to
hospitalize the patient or discharge them to home from
the ED did not add any value to our score. We therefore
did not include this measurement in our final model due
Figure 1 Death in exacerbation of chronic obstructive pulmonary disease: construction of continuous and categorical scores and relation with
different outcomes. ICU: Intensive Care Unit, IMV: Invasive mechanical ventilation, IRCU: Intermediate Respiratory Care Unit, LT-HOT: Long-term
home oxygen therapy, NIMV: Noninvasive mechanical ventilation. Superscript letters indicated statistical significant differences among the
DeCOPD risk classes for the outcomes displayed.
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mainly at ED decision time. Nevertheless, future studies
should evaluate the final role of these parameters in our
score, although room for improvement in its predictive
ability appears to be low.
From a practical point of view, our DeCOPD risk clas-
sification allows a clinician to identify patients who
could be discharged to home (those with mild eCOPD)
from those who should be admitted (severe and very se-
vere eCOPD) because the latter are more likely to have
an adverse event or to need intensive treatment and
closer follow-up. For patients in the moderate category,
further clinical information would be needed in the ED
to decide if they should be admitted and if they need in-
tensive treatment.
We compared our score with other rules or parame-
ters used to classify patients with COPD, such as the
ADO index, HADO score, GOLD FEV1%, and GOLD
COPD combined assessment [16,21,22,24]. In each case,
these other scores performed poorly compared with our
score. However, we must point out that those rules were
created for patients with stable COPD, not those experi-
encing exacerbations. Tabak et al. recently proposed a
prediction model derived from a large administrative
database of hospitalized patients; their model has AUCsaround 0.83, also but requires vital signs upon admission
and laboratory results [10].
Our study has several strengths. The prediction rule
we propose was created from data prospectively col-
lected from a large (n = 2,487) group of patients experi-
encing COPD exacerbations recruited from 16 different
EDs, each with its own set of guidelines or clinical prac-
tices for evaluating and treating patients with eCOPD.
This is likely to improve the generalizability of the re-
sults. The cohort included both patients admitted to the
hospital and patients who were discharged to home. Fur-
thermore, we collected a broad range of clinical vari-
ables, many of them from the ED, and tested them in
different models. We also strove to properly validate
these prediction rules, following best practices for such
studies [13,14].
The lack of data for some key variables is the main limita-
tion of our work. In a study such as this, clinical practice in
the ED prevails over research requirements. We did not ask
ED physicians to modify their clinical practices in any way.
Thus, we had to work with the information available. Occa-
sionally this led to missing data, but this did not appear to
affect the results. In the case of baseline dyspnea (measured
by the MRC scale), for example, we determined that pa-
tients with missing data had similar outcomes to those with
Table 4 Comparison of different prediction scales on short-term mortality on patients with eCOPD
Outcome N Short-term mortality P
value*
AUC 95% CI P
value**Yes No
DeCOPD score mean (sd) 2484 9.03 (4.27) 3.07 (3.4) ≤0.0001 0.85 0.79 to 0.90 Refa
DeCOPD score (categorical) 2484 ≤0.0001 0.84 0.79 to 0.89 0.38
Risk
Mild 1081 3 (0.28) 1078 (99.72)
Moderate 865 11 (1.27) 854 (98.73)
Severe 441 20 (4.54) 421 (95.46)
Very severe 97 24 (24.74) 73 (75.26)
GOLD FEV1% 2069 0.0133 0.62 0.56 to 0.69 <0.0001
FEV1% ≥80 76 0 (0.0) 76 (100)
50 ≤ FEV1% <80 643 6 (0.93) 637 (99.07)
30 ≤ FEV1% <50 959 28 (2.92) 931 (97.08)
FEV1% ≤30 391 13 (3.32) 378 (96.68)
GOLD COPD combined assessment 2090 <0.002 0.71 0.67 to 0.75 <0.0001
Low risk, low symptom burden 286 1 (0.35) 285 (99.65)
Low risk, higher symptom burden 335 4 (1.19) 331 (98.81)
High risk, low symptom burden 351 0 (0.00) 351 (100)
High risk, higher symptom burden 1118 46 (4.11) 1072 (95.89)
HADO score 1887 0.0002 0.68 0.63 to 0.72 <0.0001
Mild (<4) 188 0 188 (100)
Moderate (5 to 7) 604 3 (0.50) 601 (99.50)
Severe (>8) 1095 33 (3.01) 1062 (96.99)
ADO index (0 to 14) mean (sd) 2067 11.36 (1.71) 9.29 (2.19) ≤0.0001 0.78 0.71 to 0.84 0.05
Abbreviations: ADO age, baseline dyspnea, and airflow obstruction; AUC, area under the curve; COPD, chronic obstructive pulmonary disease; DeCOPD, Death in
exacerbation of chronic obstructive pulmonary disease; ED, emergency department; FEV, forced expiratory volume; GOLD, Global Initiative for Chronic Obstructive
Lung Disease; HADO, health, activity, dyspnea, and airflow obstruction; LTHOT; long-term home oxygen therapy; MRC, Medical Research Council; NIMV,
non-invasive mechanical ventilation; PCO2 carbon dioxide partial pressure; PO2, oxygen partial pressure.
aReference value.
*p-value of the relationship of each parameter with short-term mortality.
**p-value or the comparison of areas under Receiver Operating Characteristic Curves with respect to the AUC of the DECOPD continuous scale.
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was not affected by leaving these patient in the calculations
or removing them.
It must also be noted that the patient population was
almost entirely comprised of men (97%). Similar gender
distributions have been observed in other studies per-
formed in our country [30], which probably reflects the
smoking patterns in Spain in the mid-20th century. Al-
though we do not consider this to be a serious limita-
tion, it could affect the generalizability of the results.
Finally, we did not include any biomarkers. At the
time this study was conducted, several biomarkers were
being evaluated for eCOPD (C-reactive protein, procalci-
tonin, copeptin, pro-adrenomedullin, pro-endothelin,
and B-type natriuretic peptide). However, these were not
routinely employed in the ED or in the hospital [31].
Whether these biomarkers add value to scores based on
clinical variables will be the aim of future studies.Conclusions
We developed a clinical prediction rule for a critical out-
come, death, for patients attending an ED with eCOPD.
The five variables included in our model are easily avail-
able in the ED (and also in primary care settings) and
the score is easy to estimate. This clinical prediction
rule could be employed in the clinical management of
patients with eCOPD to guide their treatment and
follow-up by in the ED and also by primary care physi-
cians. Future studies are needed for validation of this
prediction rule and to further demonstrate its value in
clinical practice.
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